biostudies-literatureUnknown43(4)Wan Mohd Zawawi WFAUniversiti Teknologi MalaysiaBreast cancer remains the leading cause of cancer-related deaths among women worldwide. Combinatorial therapies are often employed to improve treatment efficacy and reduce the risk of recurrence. Hyperthermia (HT), a minimally invasive treatment, has shown potential to enhance immunotherapy outcomes. In the EMT6 breast tumor model, elevated CD200 expression is associated with tumor progression, and blockade of the CD200/CD200R signaling pathway has been reported to enhance anti-tumor immune responses. This study presents a preliminary evaluation of the therapeutic effects of local HT combined with anti-CD200 blockade in a preclinical mouse model. EMT6 tumors were established in Balb/c mice via subcutaneous inoculation. Local HT was applied on days 7, 8, and 9 post-inoculation, and anti-CD2Medical oncology (Northwood, London, England)160https://www.ebi.ac.uk/biostudies/studies/S-EPMC12945981biostudies-literatureTherapeutic exploration of combined local hyperthermia and anti-CD200 blockade therapy in the EMT6 breast cancer model.PMC12945981Loh KMMohd Salim MIAbdul Wahab AJemon KWan Mohd Zawawi WFAfalseTherapeutic exploration of combined local hyperthermia and anti-CD200 blockade therapy in the EMT6 breast cancer model.Breast cancer remains the leading cause of cancer-related deaths among women worldwide. Combinatorial therapies are often employed to improve treatment efficacy and reduce the risk of recurrence. Hyperthermia (HT), a minimally invasive treatment, has shown potential to enhance immunotherapy outcomes. In the EMT6 breast tumor model, elevated CD200 expression is associated with tumor progression, and blockade of the CD200/CD200R signaling pathway has been reported to enhance anti-tumor immune responses. This study presents a preliminary evaluation of the therapeutic effects of local HT combined with anti-CD200 blockade in a preclinical mouse model. EMT6 tumors were established in Balb/c mice via subcutaneous inoculation. Local HT was applied on days 7, 8, and 9 post-inoculation, and anti-CD22026-01-01T00:00:00Z2026 Feb2026-07-16T22:18:14.316Z2026-07-11T03:11:48.179ZS-EPMC129459814174655010.1007/s12032-026-03240-7